Mycotoxin Exposure and Related Diseases

Assunção, Ricardo; Viegas, Susana

doi:10.3390/toxins12030172

Cited by 6 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, Xu et al found 100% positivity for DON, 68.7% for ZEA, and 99.5% for deoxynivalenol-3-glucoside (DON-3-G) among 370 wheat samples in Anhui Province, China [8]. Exposure to mycotoxins has been linked to various chronic diseases, including neurodegenerative issues, cardiovascular disease, chronic enteritis, and endemic diseases [9][10][11]. Acute mycotoxin poisoning can be fatal to both animals and humans [12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lycopene as a Therapeutic Agent against Aflatoxin B1-Related Toxicity: Mechanistic Insights and Future Directions

Li,

Tang,

Peng

et al. 2024

Antioxidants

View full text Add to dashboard Cite

Aflatoxin (AFT) contamination poses a significant global public health and safety concern, prompting widespread apprehension. Of the various AFTs, aflatoxin B1 (AFB1) stands out for its pronounced toxicity and its association with a spectrum of chronic ailments, including cardiovascular disease, neurodegenerative disorders, and cancer. Lycopene, a lipid-soluble natural carotenoid, has emerged as a potential mitigator of the deleterious effects induced by AFB1 exposure, spanning cardiac injury, hepatotoxicity, nephrotoxicity, intestinal damage, and reproductive impairment. This protective mechanism operates by reducing oxidative stress, inflammation, and lipid peroxidation, and activating the mitochondrial apoptotic pathway, facilitating the activation of mitochondrial biogenesis, the endogenous antioxidant system, and the nuclear factor erythroid 2-related factor 2 (Nrf2)/kelch-like ECH-associated protein 1 (KEAP1) and peroxisome proliferator-activated receptor-γ coactivator-1 (PGC-1) pathways, as well as regulating the activities of cytochrome P450 (CYP450) enzymes. This review provides an overview of the protective effects of lycopene against AFB1 exposure-induced toxicity and the underlying molecular mechanisms. Furthermore, it explores the safety profile and potential clinical applications of lycopene. The present review underscores lycopene’s potential as a promising detoxification agent against AFB1 exposure, with the intent to stimulate further research and practical utilization in this domain.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Exposure to mycotoxins has been linked to various chronic diseases, including neurodegenerative issues, cardiovascular disease, chronic enteritis, and endemic diseases [9][10][11]. Acute mycotoxin poisoning can be fatal to both animals and humans [12].…”

Section: Introductionmentioning

confidence: 99%

Lycopene as a Therapeutic Agent against Aflatoxin B1-Related Toxicity: Mechanistic Insights and Future Directions

Li,

Tang,

Peng

et al. 2024

Antioxidants

View full text Add to dashboard Cite

show abstract

“…There exist various types of mycotoxins, with a atoxin (AFB), zearalenone (ZEN), ochratoxin (OTA), and deoxynivalenol (DON) being the most wellknown ones. These mycotoxins pose a serious threat to human and animal health (Assunção et al 2020;Patrícia et al 2021).…”

Section: Introductionmentioning

confidence: 99%

Biodetoxification of both AFB1 and ZEN by Bacillus subtilis ZJ-2019-1 in gastrointestinal environment and in mice

Wu,

An,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

Aflatoxin B1 (AFB1) and zearalenone (ZEN) are the most prevalent mycotoxins in production, posing a serious threat to the food and feed industry and resulting in a substantial economic burden. Therefore, finding a safe and efficient method for biodegradation of mycotoxins is of utmost important in addressing this issue. Bacillus subtilis ZJ-2019-1, capable of degrading AFB1 and ZEN, was isolated and cultured in our laboratory in vitro. In this study, we conducted detoxification tests on AFB1 and ZEN using B. subtilis ZJ-2019-1 in gastrointestinal environment and in mice, respectively. Our findings demonstrate that B. subtilis ZJ-2019-1 can effectively degrade both mycotoxins present in feed within gastrointestinal environment. Following degradation by B. subtilis ZJ-2019-1, the toxicity of the AFB1 and ZEN product decreased compared to their original levels. Furthermore, B. subtilis ZJ-2019-1 exhibited excellent detoxification effects on AFB1 and ZEN when tested in mice. These results indicate that B. subtilis ZJ-2019-1 possesses the ability to degrade both AFB1 and ZEN, making it suitable for application in the food and feed industry as a means to reduce economic losses caused by mycotoxins.

show abstract

The sensor protein AaSho1 regulates infection structures differentiation, osmotic stress tolerance and virulence via MAPK module AaSte11-AaPbs2-AaHog1 in Alternaria alternata

Liu,

Yuan,

et al. 2024

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

Mycotoxin Exposure and Related Diseases

Abstract: Mycotoxins are considered the most frequently occurring natural contaminants in the diet of humans and animals [...]

Cited by 6 publications

References 25 publications

Lycopene as a Therapeutic Agent against Aflatoxin B1-Related Toxicity: Mechanistic Insights and Future Directions

Lycopene as a Therapeutic Agent against Aflatoxin B1-Related Toxicity: Mechanistic Insights and Future Directions

Biodetoxification of both AFB1 and ZEN by Bacillus subtilis ZJ-2019-1 in gastrointestinal environment and in mice

The sensor protein AaSho1 regulates infection structures differentiation, osmotic stress tolerance and virulence via MAPK module AaSte11-AaPbs2-AaHog1 in Alternaria alternata

Contact Info

Product

Resources

About